Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527097 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL7522233 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL2826921 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL3674735 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL3676137 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL7523498 | 0.95 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL11043908 | 0.95 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL7523506 | 0.95 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| SCHEMBL7523503 | 0.95 | CYP3A4 (0.39) | CYP3A4TDP1GAAALDH1A1CHRNB2 | |
| Carbon Monoxide SCHEMBL11047074 | 0.91 | NPSR1 (0.35) | CYP3A4TDP1GAAALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309779-B2 | Ethylene oligomerization catalyst systems having enhanced selectivity | SK INNOVATION CO., LTD. (KR) | 2012-11-13 | — | — | US | claimed |
| US-9469662-B2 | Process for preparing optically active biophosphinylalkanes | BASF SE (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9469662-B2 | Process for preparing optically active biophosphinylalkanes | BASF SE (DE) | 2016-10-18 | — | — | US | disclosed |
| US-8309779-B2 | Ethylene oligomerization catalyst systems having enhanced selectivity | SK INNOVATION CO., LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20100145124-A1 | ETHEYENE OLIGOMERIZA CATALYST SYSTEMS HAVING ENEHANCED SELECTIVITY | SK INNOVATION CO., LTD. (KR) | 2010-06-10 | — | — | US | disclosed |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080214857-A1 | Method Of Reducing A Functional Group In An Oxidized Form | RHODIA CHIMIE (FR) | 2008-09-04 | — | — | US | disclosed |
| US-20080214857-A1 | Method Of Reducing A Functional Group In An Oxidized Form | RHODIA CHIMIE (FR) | 2008-09-04 | — | — | US | disclosed |
| WO-2007012655-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2007-02-01 | — | — | WO | disclosed |
| EP-1182205-A1 | Chiral diphosphines via 2,3 -sigmatropic rearrangement.Application in asymmetric transition metal catalysis | PPG-Sipsy S.C.A. (FR) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214857-A1 | Method Of Reducing A Functional Group In An Oxidized Form | NOX1, NOXO1, NOX5 | CYP3A4 554/4885TDP1 3957/4885GAA 1441/4885 |
| US-20100145124-A1 | ETHEYENE OLIGOMERIZA CATALYST SYSTEMS HAVING ENEHANCED SELECTIVITY | CBR3, ESR2, ESR1 | CYP3A4 3020/4885TDP1 3577/4885GAA 4043/4885 |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | PHOSPHO1, DCTPP1, DCPS | CYP3A4 807/4885TDP1 4215/4885GAA 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.